Nine Months 2025 Valneva SE Earnings Call Transcript
Key Points
- Valneva SE (INRLF) reported a 9% increase in total revenues, reaching EUR127 million for the first nine months of 2025.
- The company successfully reduced its operating cash burn, resulting in a cash position of over EUR140 million.
- Valneva SE (INRLF) completed its debt refinancing, enhancing financial flexibility with a new partner, Pharmaon.
- The company secured additional marketing authorizations for its products in the UK and Brazil, and label extensions in Europe and Canada.
- Positive phase 1 results were reported for the second-generation Zika vaccine candidate VLA 1,601, indicating promising development.
- Valneva SE (INRLF) faced a temporary restriction and US license suspension for its chikungunya vaccine, adversely impacting sales in the traveler segment.
- The company reported an operating loss of EUR53.9 million for the first nine months of 2025, compared to an operating profit in the prior year.
- Research and development expenses increased significantly, driven by costs related to the Shigella vaccine candidate and Ichick phase 4 commitments.
- Third-party product sales decreased by 28.5% year-over-year, reflecting the anticipated discontinuation of certain distribution agreements.
- Uncertainty around private and public funding opportunities poses a challenge for advancing the Zika vaccine candidate.
Hello and thank you for joining us to discuss Valneva's financial results for the first nine months of 2025 and corporated. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the nine months ended September 30, 2025, which were published earlier today, available within the financial reports section of our investor website.
I'm joined today by Valneva's CEO, Thomas Lingelbach; and our CFO, Peter Buhler, who will provide an overview and update on our business as well as our key financial results for the first half. There will be an analyst Q&A session at the conclusion of the prepared remarks. Before we begin, I'd like to remind listeners that during this presentation, we will be making forward-looking statements, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
You can find additional information
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
